Asset Details
Do you wish to reserve the book?
Impact of obesity on catheter ablation of ventricular tachycardia: In‐hospital and 30‐day outcomes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of obesity on catheter ablation of ventricular tachycardia: In‐hospital and 30‐day outcomes
Do you wish to request the book?
Impact of obesity on catheter ablation of ventricular tachycardia: In‐hospital and 30‐day outcomes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of obesity on catheter ablation of ventricular tachycardia: In‐hospital and 30‐day outcomes
2023
Overview
Background Evidence on the impact of obesity on catheter ablation for ventricular tachycardia (VT) is scarce. Method and Results We queried the Nationwide Readmissions Database to determine the hospital outcomes and procedural complications of VT ablation among the obese and nonobese populations. Obesity was associated with a more prolonged length of stay (p < .01), higher cost of hospitalization (p < .01), and higher rates of pericardial effusion or hemopericardium (p = .05) and vascular complications (p = .05). There was no significant difference in early mortality, 30‐day readmissions, and other procedural complications. Conclusion VT ablation could be performed relatively safely among patients with obesity. Our manuscript analyses the in‐hospital procedural outcomes of catheter ablation for VT between obese and non‐obese patients and found that VT ablation in obese patients has no significant difference in 30‐day mortality or 30‐day readmissions, but they do have increased vascular and pericardial effusion or hemopericardium complication rates, prolonged hospital stay (>7 days), and cost of hospitalization.
